ATAI
Atai Beckley NV
NASDAQ · Healthcare · Medical - Pharmaceuticals · NL
$7.39
+0.68%Year over year
Reported trailing growth
- Revenue
- +93.7%
- EBITDA
- —
- EBIT
- -48.7%
- EPS
- —
- Free cash flow
- -64.4%
- Operating cash flow
- -69.1%
Forward estimates
Based on analyst estimates
- Revenue
- -4.8%
- EBITDA
- +74.6%
- EPS
- +83.5%
Three-year CAGR
- Revenue
- +159.9%
- EBITDA
- —
- EBIT
- +2.9%
- Net income
- —
- EPS
- —
- Free cash flow
- -25.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026